BEGIN:VCALENDAR VERSION:2.0 PRODID:-//wp-events-plugin.com//7.2.2.1//EN TZID:America/Toronto X-WR-TIMEZONE:America/Toronto BEGIN:VEVENT UID:143@womenshealthresearchcluster.com DTSTART;TZID=America/Vancouver:20230123T040000 DTEND;TZID=America/Vancouver:20230123T050000 DTSTAMP:20250106T204621Z URL:https://womenshealthresearchcluster.com/events/aug-23-2022-translating -spectrum-sex-differences-cancer-biology-sex-adapted-treatments/ SUMMARY:Translating the Spectrum of Sex Differences in Cancer Biology into Sex-adapted Treatments DESCRIPTION:\n\n\nSeminar Title: \;Translating the Spectrum of Sex D ifferences in Cancer Biology into Sex-adapted Treatments\n\nPresenter:&nbs p\;Dr. Joshua B. Rubin\, \;Professor of Pediatrics and Neuroscience\,& nbsp\;Washington University \;School of Medicine\n\nDr. Rubin is a Pro fessor of Pediatrics and Neuroscience at Washington University School of M edicine in St. Louis. He is originally from Ardsley\, New York and is a gr aduate of Yale University. Dr. Rubin went on to receive his MD and PhD fro m the Albert Einstein College of Medicine in New York City. Following grad uation\, he completed a residency in Pediatrics at Boston&rsquo\;s Childre n&rsquo\;s Hospital and a fellowship in Pediatric Hematology and Oncology at the Dana Farber Cancer Institute and Harvard Medical School where he tr ained in pediatric neuro-oncology with Dr. Mark Kieran. At the Dana Farber Cancer Institute\, Dr. Rubin completed his post-doctoral training in the laboratory of Dr. Rosalind Segal.\n\nIn 2003\, Dr. Rubin was recruited to Washington University where he established his research lab and co-founded the Pediatric Neuro-Oncology Program at St. Louis Children&rsquo\;s Hospi tal. In the clinic\, his research activities include many therapeutic clin ical trials and a significant focus on understanding the basis for cogniti ve deficits after treatment for pediatric brain tumors. The focus in his l aboratory is on links between normal brain development and the genesis of brain tumors\, especially those aspects of development that render males m ore vulnerable to brain tumors than females\, and the development of novel therapeutics.\n\nTalk Summary: \;While sex differences in cancer risk and survival are obvious\, translation of these differences into sex-adap ted treatments remains elusive. Central to the challenge is that cancer ph enotypes\, like sex differences in height\, exist on a spectrum with two h ighly overlapping distributions of male and female values. Thus\, sex-adap ted treatments are not likely to be dichotomous male- versus female- speci fic approaches\, and more likely to target an individual&rsquo\;s unique m ix of male- and female- biased biology. In this talk\, we will discuss usi ng whole transcriptomes to define an individual patient&rsquo\;s admixture of male and female biology for the purpose of personalized sex-adapted tr eatment strategies.\n\n\n\n ATTACH;FMTTYPE=image/jpeg:https://womenshealthresearchcluster.com/wp-conte nt/uploads/2024/11/website_event_photo-15.jpg CATEGORIES:Women’s Health Seminar Series END:VEVENT BEGIN:VTIMEZONE TZID:America/Vancouver X-LIC-LOCATION:America/Vancouver BEGIN:STANDARD DTSTART:20221106T010000 TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST END:STANDARD END:VTIMEZONE END:VCALENDAR